Drug Discovery

Eiger shuns plans to seek EUA from US FDA for Covid-19 treatment

Eiger BioPharmaceuticals has announced that it will not seek emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for peginterferon lambda to treat mild-to-moderate Covid-19 patients.

Alexion, AstraZeneca to buy LogicBio Therapeutics

Alexion, AstraZeneca Rare Disease has signed a deal to buy genomic medicine company LogicBio Therapeutics.

AeroRx, HCmed to develop nebulised combination formulation for COPD

AeroRx Therapeutics has collaborated with HCmed Innovations to develop a long-acting beta-agonist (LABA) / long-acting muscarinic antagonist (LAMA) combination solution to treat chronic obstructive pulmonary disease (COPD).

Vanda partners with OliPass to develop ASO-based therapeutics

Vanda Pharmaceuticals signed a research and development collaboration agreement with OliPass to jointly develop antisense oligonucleotide (ASO) therapeutics.

ArsenalBio, Genentech partner to identify T-Cell therapies for cancer

Arsenal Biosciences and Genentech have entered a multi-year collaboration for identifying features of T-Cell therapies for oncology.

Sciwind, SynerK to develop novel therapeutics for liver and metabolic diseases

Clinical-stage biopharmaceutical firm Sciwind Biosciences has signed a research partnership agreement with RNAi therapeutics company SynerK for the joint development of novel therapeutics to treat liver and metabolic diseases.

NETRIS Pharma, Orano and CLB partner to develop new radio-conjugates

NETRIS Pharma, Orano and Centre Léon Bérard (CLB) have entered into a scientific collaboration agreement for the development of new antibody radio-conjugates to treat cancer.

FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine

The US Food and Drug Administration (FDA) has accepted for priority review Seagen’s supplemental New Drug Application (sNDA) seeking accelerated approval for its medicine tukysa (tucatinib) along with trastuzumab to treat colorectal cancer.

NeuroBo signs license deal with Dong-A ST to develop two drug candidates

NeuroBo Pharmaceuticals has signed a conditional exclusive license agreement with Dong-A ST for the development and commercialisation of the latter’s cardio-metabolic therapies, DA-1241 and DA-1726.